Zenex Animal Health appoints Aniruddha Rajurkar as CEO to steer next growth phase

INDIA – India-based animal health company Zenex Animal Health has appointed Aniruddha Rajurkar as Chief Executive Officer as it accelerates its expansion across animal health and nutrition markets.

Rajurkar brings more than 25 years of experience spanning animal health, pharmaceuticals, CDMO, women’s health and over-the-counter segments. 

He has held leadership roles across both scaled and startup environments, with a focus on strategic operations and business transformation.

In his new role, Rajurkar will oversee all organisational functions and work closely with the board to drive execution, innovation and long-term growth. 

The leadership transition comes at a time when Zenex is positioning itself to scale globally, particularly in high-growth segments such as preventive animal health and natural nutrition solutions.

Welcoming the appointment, Renuka Ramnath, Chairperson of Zenex Animal Health, said, “With a proven track record of leadership and strategic insight, Aniruddha brings the vision and capability needed to guide Zenex Animal Health into its next phase of growth.”

She added that the transition will be supported by continuity at the executive level, with Arun Atrey remaining Managing Director and Board Member. 

“Dr Atrey will continue to support the organisation by mentoring the incoming CEO while focusing on key strategic initiatives,” she said.

Atrey will now concentrate on inorganic growth, partnerships and regulatory affairs, while continuing to provide strategic direction as Zenex expands its footprint across international markets.

Acquisition of VievePharm strengthens naturals portfolio and EU footprint

The leadership change follows Zenex’s strategic acquisition of a majority stake in VievePharm in February 2026, marking a significant step in its global expansion strategy.

The Netherlands-based company specialises in phytogenic formulations for livestock, equine and pet care markets, and operates a certified manufacturing facility serving more than 60 customers across over 25 countries. 

The acquisition provides Zenex with an operational base in Western Europe, strengthening its access to EU markets and enhancing its export capabilities.

Commenting on the deal, Atrey said, “The acquisition of VievePharm is a logical progression of our first-principles approach to animal healthcare, focusing on prevention and sustainable productivity.”

He added that combining VievePharm’s bolus technology and European presence with Zenex’s research and distribution network would enable the company to deliver more integrated, science-backed solutions globally.

The transaction also aligns with growing regulatory and market demand for alternatives to antibiotics, particularly in Europe.

In Europe, policy frameworks such as the EU Farm to Fork Strategy are accelerating the shift toward natural and sustainable animal health solutions.

Arie Boorsma, Founder of VievePharm, said, “Joining forces with Zenex allows us to scale our ‘Best of Nature’ philosophy to a global stage. 

This partnership will provide the resources and reach necessary to deepen our operations in the Netherlands and expand across international markets.”

For Zenex, the integration of VievePharm strengthens its position in the fast-growing naturals segment, while also adding advanced bolus manufacturing capabilities for minerals, vitamins and animal health applications.

Sign up HERE to receive our email newsletters with the latest news updates and insights from Africa and the World, and follow us on our WhatsApp channel for updates.